Legend Biotech Corporation Stock price

Equities

LEGN

US52490G1022

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-02-21 pm EST 5-day change 1st Jan Change
59.83 USD -0.45% Intraday chart for Legend Biotech Corporation +3.46% -0.57%
Sales 2023 * 297M Sales 2024 * 572M Capitalization 10.88B
Net income 2023 * -480M Net income 2024 * -297M EV / Sales 2023 * 34.6 x
Net cash position 2023 * 577M Net cash position 2024 * 364M EV / Sales 2024 * 18.4 x
P/E ratio 2023 *
-36.2 x
P/E ratio 2024 *
-63.4 x
Employees 1,700
Yield 2023 *
-
Yield 2024 *
-
Free-Float 0%
More Fundamentals * Assessed data
Dynamic Chart
Genscript Biotech Unit Rakes in $159 Million in Sales for Myeloma Treatment; Shares Rise 4% MT
Genscript Biotech Unit to Submit More Data to European, US Authorities for Approval of Myeloma Drug MT
Legend Biotech Provides Update on U.S. FDA and EMA Applications for Expanded Use of CARVYKTI® (ciltacabtagene autoleucel) in Earlier Lines of Treatment for Relapsed/Refractory Multiple Myeloma CI
US FDA requires 'boxed warning' for CAR-T cancer therapies RE
FDA REQUIRES GILEAD, JNJ, NOVARTIS, BRISTOL MYERS SQUIBB, 2SEVEN… RE
Genscript, Legend Biotech On-Track to Begin Production at Ghent Facilities This Year MT
Transcript : Legend Biotech Corporation Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 02:15 PM
Genscript Biotech's Subsidiary Legend Closes License Agreement with Novartis for Anti-Cancer Drug MT
Legend Biotech Closes Licensing Agreement with Novartis for CAR-T Therapies MT
RBC Trims Price Target on Legend Biotech to $85 From $86, Keeps Outperform Rating MT
Legend Biotech Corporation Announces Closing of License Transaction for Certain Car-T Therapies Targeting DLL3 with Novartis Pharma AG CI
Legend Biotech Announces U.S. FDA Label Update for CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) CI
Genscript Biotech Unit Secures US FDA Nod for Carvykti Label Update MT
Scotiabank Initiates Legend Biotech With Sector Perform Rating, $65 Price Target MT
Genscript Biotech's US Subsidiary Presents Positive Results of Carvykti Drug from Phase 3 Study MT
More news
1 day-0.45%
1 week+3.46%
Current month+8.66%
1 month+5.56%
3 months+4.51%
6 months-12.12%
Current year-0.57%
More quotes
1 week
56.82
Extreme 56.82
60.50
1 month
51.07
Extreme 51.07
61.85
Current year
51.07
Extreme 51.07
61.85
1 year
42.91
Extreme 42.905
77.32
3 years
23.41
Extreme 23.41
77.32
5 years
23.41
Extreme 23.41
77.32
10 years
23.41
Extreme 23.41
77.32
More quotes
Managers TitleAgeSince
Chief Executive Officer 51 19-06-30
Director of Finance/CFO 53 19-08-31
Chief Tech/Sci/R&D Officer - 18-04-30
Members of the board TitleAgeSince
Chief Executive Officer 51 19-06-30
Director/Board Member 67 20-04-30
Director/Board Member 74 20-11-22
More insiders
Date Price Change Volume
24-02-21 59.83 -0.45% 471,380
24-02-20 60.1 +3.42% 749,279
24-02-16 58.11 +1.86% 690,492
24-02-15 57.05 -1.35% 708,519
24-02-14 57.83 -1.43% 426,696

Delayed Quote Nasdaq, February 21, 2024 at 04:00 pm EST

More quotes
Legend Biotech Corporation is a global biotechnology company, which is focused on developing, manufacturing and commercializing novel therapies to treat life-threatening diseases. The Company is developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell and natural killer (NK) cell-based immunotherapy. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), is a CAR-T cell therapy for the treatment of multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It is also developing an allogeneic gamma delta CAR-T product candidate targeting B-cell maturation antigen for MM.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
59.83 USD
Average target price
86.29 USD
Spread / Average Target
+44.22%
Consensus
  1. Stock
  2. Equities
  3. Stock Legend Biotech Corporation - Nasdaq
+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019
Replicate our performance
fermer